Advanced Search

 

Study ID Status Title Patient Level Data
NAI30008 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study To Investigate The Efficacy And Safety Of Zanamivir (GG167) 10mg Administered Twice A Day For Five Days In The Treatment Of Influenza In Patients 12 Years Or Over With Asthma Or Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
NAI30009 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5-12. Study Listed on ClinicalStudyDataRequest.com
NAI30010 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within families. Study Listed on ClinicalStudyDataRequest.com
NAI30011 Completed A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Impact of Inhaled Zanamivir Treatment on Workplace Attendance Due to Influenza A and B Infections Study Listed on ClinicalStudyDataRequest.com
NAI30012 Completed A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Subjects Aged >= 65 Years. Study Listed on ClinicalStudyDataRequest.com
NAI30015 Completed A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel. Study Listed on ClinicalStudyDataRequest.com
NAI30020 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice a Day for Five Days in the Treatment of Symptomatic influenza A and B Viral Infections in High Risk Patients Study Listed on ClinicalStudyDataRequest.com
NAI30028 Completed A Double-Blind,Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Twice a Day for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Children. Study Listed on ClinicalStudyDataRequest.com
NAI30031 Completed A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day for 10 Days in the Prevention of Transmission of Symptomatic Influenza A and B Viral Infections within Households Study Listed on ClinicalStudyDataRequest.com
NAI30034 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Once a Day for 28 Days in the Prevention of Symptomatic Influenza A and B Viral Infections in Community-Dwelling High-risk … Study Listed on ClinicalStudyDataRequest.com
NAIA1001 Completed A Study to Investigate the Effect of Intranasal GR121167X on Infection Rates in Healthy Male Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) virus Study Listed on ClinicalStudyDataRequest.com
NAIA1002 Completed A Study to Investigate the Effect of Intranasal GG167 Initiated at Various Intervals Post Inoculation on Infection in Healthy Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus Study Listed on ClinicalStudyDataRequest.com
NAIA1003 Completed A Study to Investigate the Effect of Intranasal GG167 at Various Dosing Frequencies on Infection in Healthy Volunteers when Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus Study Listed on ClinicalStudyDataRequest.com
NAIA1004 Completed A Study to Investigate the Effect of Intranasal GG167 as Nasal Drops and Nasal Spray on Infection in Healthy Volunteers Experimentally Inoculated with Influenza A/Texas/91 (H1N1) Virus Study Listed on ClinicalStudyDataRequest.com
NAIA1005 Completed A Study to Investigate the Effect of Intranasal GG167 on Infection in Healthy Volunteers Experimentally Inoculated with Influenza B/YAMAGATA/16/88 Virus Study Listed on ClinicalStudyDataRequest.com
NAIA1009 Completed Pharmacokinetics of zanamivir (GG167) following inhaled administration in pediatric subjects with signs and symptoms of respiratory illness. Study Listed on ClinicalStudyDataRequest.com
NAIA2005 Completed A Double-Blind, Randomized Placebo-Controlled Multicenter Study to Investigate the Efficacy and Safety of GG167 in the Treatment of Influenza A and B Infection Study Listed on ClinicalStudyDataRequest.com
NAIA2006 Completed A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Investigate the Efficacy and Safety of GG167 (Zanamivir) Therapy in the Prevention of Progression of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIA2008 Completed A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel and Group Study to Investigate the Efficiacy and Safety of GG167 Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIA2009 Completed A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of GG167 in the Prevention and/or Progression of Influenza A and B Viral Infections Study Listed on ClinicalStudyDataRequest.com
NAIA2010 Completed Efficacy of Zanamivir (GG167) in Controlling Nursing Home Influenza Outbreaks Study Listed on ClinicalStudyDataRequest.com
NAIA3002 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. Study Listed on ClinicalStudyDataRequest.com
NAIA3003 Completed A Double-Blind, Randomized, Parallel-Group, Multi-Center Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day Compared to the Standard of Care in Controlling Nursing Home Influenza Outbreaks Study Listed on ClinicalStudyDataRequest.com
NAIA3004 Completed A double-blind, randomized, placebo-controlled, parallel-group, multi-center study to investigate the efficacy and safety of inhaled zanamivir 10 mg once a day in controlling nursing home influenza outbreaks. Study Listed on ClinicalStudyDataRequest.com
NAIA3005 Completed A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community dwelling adults. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.